TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00508066
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, 4ml/hour for 72 hours.
Study: NCT04227015
Drug: CTA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTA101 UCAR-T cell injection by intravenous infusion
Study: NCT04000282
Drug: SAR442085
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
Study: NCT04474002
Drug: 4L Klean Prep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
Study: NCT04474002
Drug: 1L Klean prep® and 2 sachets Picoprep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
Study: NCT00275197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01154920
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
Study: NCT01849237
Drug: Standard therapy of septic shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Study: NCT04768699
Drug: TQG203
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Study: NCT03681249
Drug: ShenqiDihuang Decoction placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
Study: NCT04768699
Drug: TQG203/NovoSeven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
Study: NCT04768699
Drug: TQG203
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Study: NCT02019160
Drug: 25% AgNO3 solution followed by 5% NaF varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of 4.4μg±1.4μg fluoride per use
Study: NCT02019160
Drug: 38% SDF solution followed by placebo varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of 8.8μg±2.8μg fluoride per use
Study: NCT00454051
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
Study: NCT01628029
Drug: Therapeutic Melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02614716
Drug: LY3090106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02614716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02242864
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242864
Drug: MicardisPlus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01350245
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
Study: NCT00866359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)
Study: NCT05565430
Drug: Effects of anticholinergic medication
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
Study: NCT02500576
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04639284
Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
Study: NCT01433055
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
Study: NCT01433055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
Study: NCT02717455
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.
Study: NCT02115490
Drug: Bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00733005
Drug: Matching placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study: NCT04552353
Drug: Vaway
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Study: NCT01564537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib placebo-matching capsules
Study: NCT00880178
Drug: Simvastatin and Extended-Release niacin
Normalized name: niacin / simvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT00880178
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT00591773
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT00591773
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT00591773
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT00825760
Drug: Topical placebo gel plus light
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ribociclib
Study: NCT04173104
Drug: [18F]PARPi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Study: NCT02998697
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose 200 mg t.i.d for 90 days
Study: NCT01808547
Drug: ISV-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% bromfenac in DuraSite dosed BID
Study: NCT04459039
Drug: 250 mL 0.9% sterile saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
Study: NCT01068145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match SCH 527123, once daily for 7 days
Study: NCT01068145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match SCH 527123, once daily for 14 days
Study: NCT06785493
Drug: Optimized Treatment (OPT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the first sufficient intravenous infusion of UST (6 mg/kg), the patient's response was assessed based on PRO2 at week 8, and an individualized treatment plan was developed. At week 8, the patients with incomplete response of PRO2 (a decline of PRO2 was less than 50% from baseline or still in moderate to severe active phase of PRO2) were given one or more UST intravenous re-induction (6 mg/kg) every 4 or 6 weeks.
Study: NCT00038077
Drug: Seloken ZOK/Toprol-XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg
Study: NCT00038077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507311
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose injected subcutaneously (under the skin)
Study: NCT00451204
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol 8 mg capsule, once per day, duration of treatment is 2 years
Study: NCT00451204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, once a day, treatment duration is 2 years
Study: NCT03968822
Drug: Intralipid, 20% Intravenous
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 250ml bag administered intravenously
Study: NCT00699426
Drug: placebo+placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo and placebo are tested.
Study: NCT00711880
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT00711880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT04505566
Drug: Ketorolac 0.45% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Study: NCT04505566
Drug: Placebo - Preservative-free artificial tears
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Study: NCT02779166
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Received 400mg celecoxib prior to surgery
Study: NCT02779166
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00317694
Drug: Fermagate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet 500mg
Study: NCT00317694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, film coated tablet, 0mg
Study: NCT03180281
Drug: SU
Normalized name: SUMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1-2mg qd
Study: NCT03973268
Drug: Arm 1, 2, 3 drug Interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine
Study: NCT03973268
Drug: Arm 1 and 2 Interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel
Study: NCT04267887
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given ADT per standard of care
Study: NCT06789497
Drug: Lovastatin 60 MG
Normalized name: lovastatin 60 MG
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were given lovastatin 60 mg/day for three consecutive days.
Study: NCT06789497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were given placebo 60 mg/day for three consecutive days.
Study: NCT03907124
Drug: Genetically-guided treatment with FDA-approved psychotropic drugs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
Study: NCT03907124
Drug: Treatment as usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
Study: NCT02115594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04678492
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Study: NCT00130533
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00515502
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
Study: NCT00639873
Drug: quinine-doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinine-doxycycline for 7 days
Study: NCT01059565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Study: NCT03317002
Drug: AZD5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of AZD5718 (tablet)
Study: NCT03317002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (tablet)
Study: NCT00574587
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
Study: NCT00574587
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
Study: NCT01692782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT02139033
Drug: Retaine™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03263429
Drug: Glutaminase Inhibitor CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT04341116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive a single infusion
Study: NCT02212574
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
Study: NCT01909453
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGX818- Orally 100 mg and 50 mg capsules
Study: NCT01909453
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162- Orally 15 mg tablets
Study: NCT03626688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06794346
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive 300mcg of transdermal testosterone in cream daily for six months
Study: NCT06794346
Drug: Vaginal testosterone gel
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: women will receive 300mcg of vaginal gel testosterone daily for six months
Study: NCT02298348
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
Study: NCT04081909
Drug: Fentanyl，Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
Study: NCT01001364
Drug: Foraseq
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Study: NCT02625480
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT04021862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT00520780
Drug: Ferinject ® (Ferric carboxymaltose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
Study: NCT01015391
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
Study: NCT01654549
Drug: H.pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
Study: NCT03386279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single dose by mouth
Study: NCT04524871
Drug: TPST-1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
Study: NCT04524871
Drug: NKT2152
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKT2152 will be administered by mouth.
Study: NCT04524871
Drug: IO-108 1200 mg
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.